Advertisement
Advertisement
VRCA
Verrica Pharmaceuticals Inc. Common Stock
7.99
USDSponsored
-0.25
-3.03%
May 08, 16:00 UTC -4
Closed
After-Market
7.75
-0.24
-3.00%
VRCA Earnings Reports
Positive Surprise Ratio
VRCA beat 17 of 31 last estimates.
55%
Next Report
In 2 Days
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$4.61M
/-$0.45
Implied change from Q4 25 (Revenue/ EPS)
-9.46%
/-2.17%
Implied change from Q1 25 (Revenue/ EPS)
+34.73%
/-55.00%
Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Mar 11, 2026, VRCA reported earnings of -0.46 USD per share (EPS) for Q4 25, beating the estimate of -0.81 USD, resulting in a 43.22% surprise. Revenue reached 5.09 million, compared to an expected 4.62 million, with a 10.32% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.45 USD, with revenue projected to reach 4.61 million USD, implying an decrease of -2.17% EPS, and decrease of -9.46% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were Verrica Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.46, beating estimates by 43.22%, and revenue of $5.09M, 10.32% above expectations.
How did the market react to Verrica Pharmaceuticals Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- 0%, changed from $5.47 before the earnings release to $5.47 the day after.
When is Verrica Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Verrica Pharmaceuticals Inc. Common Stock's next earnings report?
Based on 4
analysts, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.45 and revenue of $4.61M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement